Second Publication on the Potential Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”)...

ResponseABILITY is brought to you by Eisai to help shed light on the impact of treatment response on patients with cancer and their families and the physicians who treat them